Cargando…
Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
BACKGROUND: Real‐life data on pharmacokinetics of factor (F) VIII/IX concentrates, especially extended half‐life (EHL), concentrates in large cohorts of persons with hemophilia are currently lacking. OBJECTIVES: This cross‐sectional study aimed to establish reference values for terminal half‐life (T...
Autores principales: | Versloot, Olav, Iserman, Emma, Chelle, Pierre, Germini, Federico, Edginton, Andrea N., Schutgens, Roger E. G., Iorio, Alfonso, Fischer, Kathelijn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361743/ https://www.ncbi.nlm.nih.gov/pubmed/34013558 http://dx.doi.org/10.1111/jth.15395 |
Ejemplares similares
-
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022) -
Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019) -
Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021) -
FVIII inhibitors display FV‐neutralizing activity in the prothrombin time assay
por: Arsiccio, Andrea, et al.
Publicado: (2021) -
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
por: Chelle, Pierre, et al.
Publicado: (2021)